Cleveland, OH September 04, 2026 --(PR.com)-- Asclepii has been selected to exhibit Poseidon, Nanosilver Hydrogel at the Vizient® Innovative Technology Exchange. Vizient, the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange Sept. 24 in Las Vegas.
The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their product or service to supply chain and clinical leaders from Vizient’s hospital clients and subject matter experts who serve on its supply councils. Each product or service will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to healthcare delivery or business models.
Asclepii’s participation in the Vizient Innovative Technology Exchange marks a milestone in the company’s commercial expansion, bringing its FDA 510(k)-cleared Poseidon™ Nanosilver Hydrogel in front of the health system leaders who shape modern wound care purchasing.
Asclepii’s work sits squarely at the intersection of clinical performance, biological safety, and accessible pricing that Vizient’s network is looking for.
“Advanced medicine has spent the last two decades getting more sophisticated, and often less accessible,” said Franco Kraiselburd, CEO and Co-Founder of Asclepii. “Vizient’s Innovative Technology Exchange is where health systems come to find solutions that reverse that trend, and Asclepii was built for exactly this conversation. We think the next generation of wound care will be defined by who it reaches, not just what it can do.”
“The Innovative Technology Exchange provides a distinctive platform for healthcare providers to engage with products and services that may influence the healthcare landscape and enhance clinical care or organizational business models,” said Kelly Flaharty, associate vice president of contract operations, Vizient. “We are pleased to extend an invitation to Asclepii to participate in the Exchange.”
The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by provider-led councils. Since 2003, Vizient has reviewed over 1,700 product submissions as part of its Innovative Technology Program.
About Asclepii
Asclepii is a Cleveland-based company delivering optimized management for modern wound care. Founded in 2022 and headquartered in Cleveland, Ohio, Asclepii develops advanced topical and regenerative products designed to make effective wound care more accessible across clinical and outpatient settings.
The company’s flagship product, Poseidon™ Nanosilver Hydrogel, is an FDA 510(k)-cleared medical device engineered with an ultra-low 1 ppm nanosilver formulation and validated to ISO 10993 biocompatibility standards. Poseidon™ is available in prescription and over-the-counter formats and is reimbursable under HCPCS code A6248 (PDAC-certified). Asclepii’s pipeline also includes Artemis Wound Matrix, a regenerative collagen-based dressing currently in development for the management of more complex chronic wounds.
Asclepii’s work is grounded in research from Case Western Reserve University and supported by clinical partnerships with Cleveland Clinic and University Hospitals. The company is committed to translating advanced medical science into products that clinicians can actually use and patients can actually afford.
For more information, visit asclepii.com or contact commercial@asclepii.com.
Artemis Wound Matrix is currently in development and has not been cleared by the FDA. Nothing in this release should be interpreted as a claim regarding an uncleared medical device.
Contact Information:
Asclepii
Franco Kraiselburd
216-672-8568
Contact via Email
asclepii.com
Read the full story here: https://www.pr.com/press-release/978312
Press Release Distributed by PR.com
